Pyxis Oncology Eyes Key MICVO Catalysts With Three September Conference Appearances

Pyxis Oncology will participate in three September 2026 investor conferences, where Interim CEO Tom Civik will discuss the company's pipeline and MICVO program. Updated Phase 1 monotherapy data in recurrent/metastatic head and neck cancer are expected in fall 2026, followed by Phase 1/2 combination data with KEYTRUDA in Q4 2026.